• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肠外表现与儿童发病炎症性肠病的疾病严重程度相关。

Extraintestinal Manifestations Are Associated With Disease Severity in Pediatric Onset Inflammatory Bowel Disease.

机构信息

Department of Pediatrics.

The Gastro Unit, Copenhagen University Hospital, Hvidovre, Denmark.

出版信息

J Pediatr Gastroenterol Nutr. 2020 Jul;71(1):40-45. doi: 10.1097/MPG.0000000000002707.

DOI:10.1097/MPG.0000000000002707
PMID:32187141
Abstract

OBJECTIVES

The aim of this study was to investigate a possible association between extraintestinal manifestations (EIM) and a more severe disease course in pediatric onset inflammatory bowel disease (pIBD).

METHODS

This study compares the disease course of pIBD patients (IBD diagnosis <15 years of age) with and without EIM in a population-based cohort from Denmark. Patients diagnosed with pIBD between 1998 and 2008 were included in the study and followed until December 31, 2014. Data on phenotype, treatment, relapses, and the temporal relationship between IBD relapses and activity of EIM were collected at end of follow-up by manual revision of patient charts.

RESULTS

Of 333 pIBD patients, 14 (4.2%) had EIM at time of diagnosis and 47 (14.1%) developed EIM during follow-up. Median follow-up time was 9.6 years for patients with EIM and 8.8 years for patients without. In ulcerative colitis, EIM were associated with an increased risk of biological treatment and surgery (hazard ratio: 2.6; 95% confidence interval [CI]: 1.3-5.5, P = 0.008 and 2.9 [95% CI: 1.1-7.7, P = 0.03], respectively). In Crohn disease, EIM were associated with an increased relapse rate (1.3 [95% CI: 1.1-1.5], P = 0.001). Lastly, we found a positive temporal relationship between relapse of IBD and EIM activity.

CONCLUSION

The presence of EIM is associated with a more severe disease course in pIBD. This should be considered when deciding treatment options, as a more aggressive treatment approach could be warranted in patients with EIM. However, prospective studies are needed to fully evaluate this.

摘要

目的

本研究旨在探讨儿童发病炎症性肠病(pIBD)中肠外表现(EIM)与更严重疾病病程之间的可能关联。

方法

本研究通过丹麦的一项基于人群的队列研究比较了伴有和不伴有 EIM 的 pIBD 患者的疾病病程。研究纳入了 1998 年至 2008 年间诊断为 pIBD 的患者,并随访至 2014 年 12 月 31 日。通过手动查阅患者病历,在随访结束时收集了表型、治疗、复发以及 IBD 复发与 EIM 活动之间的时间关系的数据。

结果

在 333 名 pIBD 患者中,14 名(4.2%)在诊断时即存在 EIM,47 名(14.1%)在随访期间出现 EIM。EIM 患者的中位随访时间为 9.6 年,无 EIM 患者的中位随访时间为 8.8 年。在溃疡性结肠炎中,EIM 与生物治疗和手术的风险增加相关(风险比:2.6;95%置信区间 [CI]:1.3-5.5,P=0.008 和 2.9 [95% CI:1.1-7.7,P=0.03])。在克罗恩病中,EIM 与更高的复发率相关(1.3 [95% CI:1.1-1.5],P=0.001)。最后,我们发现 IBD 复发与 EIM 活动之间存在正时间关系。

结论

EIM 的存在与 pIBD 更严重的疾病病程相关。在决定治疗方案时应考虑这一点,因为对伴有 EIM 的患者可能需要更积极的治疗方法。然而,需要前瞻性研究来全面评估这一点。

相似文献

1
Extraintestinal Manifestations Are Associated With Disease Severity in Pediatric Onset Inflammatory Bowel Disease.肠外表现与儿童发病炎症性肠病的疾病严重程度相关。
J Pediatr Gastroenterol Nutr. 2020 Jul;71(1):40-45. doi: 10.1097/MPG.0000000000002707.
2
Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease: Prevalence, Presentation, and Anti-TNF Treatment.儿童炎症性肠病的肠外表现:患病率、临床表现及抗TNF治疗
J Pediatr Gastroenterol Nutr. 2017 Aug;65(2):200-206. doi: 10.1097/MPG.0000000000001455.
3
Smoking increases the risk of extraintestinal manifestations in Crohn's disease.吸烟会增加克罗恩病肠外表现的风险。
World J Gastroenterol. 2014 Sep 14;20(34):12269-76. doi: 10.3748/wjg.v20.i34.12269.
4
The impact of colectomy on the course of extraintestinal manifestations in Swiss inflammatory bowel disease cohort study patients.结肠切除术对瑞士炎症性肠病队列研究患者肠外表现病程的影响。
United European Gastroenterol J. 2021 Sep;9(7):773-780. doi: 10.1002/ueg2.12125. Epub 2021 Aug 25.
5
Paediatric inflammatory bowel disease in India: a prospective multicentre study.印度儿科炎症性肠病:一项前瞻性多中心研究。
Eur J Gastroenterol Hepatol. 2020 Oct;32(10):1305-1311. doi: 10.1097/MEG.0000000000001859.
6
[Extraintestinal manifestations in inflammatory bowel disease].[炎症性肠病的肠外表现]
Ther Umsch. 2023 Dec;80(9):393-397.
7
Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort.研究背景:在炎症性肠病(IBD)患者中,vedolizumab 治疗对肠外表现的影响:一项嵌套于 OBSERV-IBD 队列的多中心队列研究。 **结论**:VED 治疗显著降低了 IBD 患者肠外表现的发生率。
Aliment Pharmacol Ther. 2018 Feb;47(4):485-493. doi: 10.1111/apt.14419. Epub 2017 Dec 18.
8
Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease.炎症性肠病患儿肠外表现的发展
Inflamm Bowel Dis. 2009 Jan;15(1):63-8. doi: 10.1002/ibd.20604.
9
[Extra-intestinal manifestation of IBD in Veszprém county (of Hungary): results of a 25-years follow-up study].[匈牙利维斯普雷姆县炎症性肠病的肠外表现:一项25年随访研究的结果]
Orv Hetil. 2003 Oct 5;144(40):1965-75.
10
Impact of Extra-Intestinal Manifestations at Diagnosis on Disease Outcome in Pediatric- and Elderly-Onset Crohn's Disease: A French Population-Based Study.诊断时肠外表现对儿童和老年起病克罗恩病疾病结局的影响:一项法国基于人群的研究。
Inflamm Bowel Dis. 2019 Jan 10;25(2):394-402. doi: 10.1093/ibd/izy254.

引用本文的文献

1
Prediction of Extraintestinal Manifestations in Inflammatory Bowel Disease Using Clinical and Genetic Variables with Machine Learning in a Latin IBD Group.在拉丁裔炎症性肠病群体中使用临床和基因变量及机器学习预测炎症性肠病的肠外表现
Int J Mol Sci. 2025 Jun 15;26(12):5741. doi: 10.3390/ijms26125741.
2
Pediatric inflammatory bowel disease: What's new and what has changed?小儿炎症性肠病:有哪些新进展和变化?
Paediatr Child Health. 2024 Mar 9;29(3):144-149. doi: 10.1093/pch/pxae013. eCollection 2024 Jun.
3
Nutritional status of pediatric patients with inflammatory bowel diseases is related to disease duration and clinical picture at diagnosis.
儿科炎症性肠病患者的营养状况与疾病持续时间和诊断时的临床特征有关。
Sci Rep. 2023 Dec 2;13(1):21300. doi: 10.1038/s41598-023-48504-8.
4
Current Role of Monoclonal Antibody Therapy in Pediatric IBD: A Special Focus on Therapeutic Drug Monitoring and Treat-to-Target Strategies.单克隆抗体疗法在儿童炎症性肠病中的当前作用:特别关注治疗药物监测和达标治疗策略。
Children (Basel). 2023 Mar 28;10(4):634. doi: 10.3390/children10040634.
5
Significant advantages for first line treatment with TNF-alpha inhibitors in pediatric patients with inflammatory bowel disease - Data from the multicenter CEDATA-GPGE registry study.肿瘤坏死因子-α抑制剂用于儿童炎症性肠病一线治疗的显著优势——来自多中心CEDATA-GPGE注册研究的数据
Front Pediatr. 2022 Jul 19;10:903677. doi: 10.3389/fped.2022.903677. eCollection 2022.
6
Increased Demand for Therapeutic Drugs in Pediatric Ulcerative Colitis Patients With Extraintestinal Manifestations.患有肠外表现的小儿溃疡性结肠炎患者对治疗药物的需求增加。
Front Pediatr. 2022 May 23;10:853019. doi: 10.3389/fped.2022.853019. eCollection 2022.
7
Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease.用于优化和个性化治疗儿童炎症性肠病中抗 TNF 药物的生物标志物
Pharmaceutics. 2021 Oct 26;13(11):1786. doi: 10.3390/pharmaceutics13111786.
8
Severe Disease Activity Based on the Paris Classification Is Associated with the Development of Extraintestinal Manifestations in Korean Children and Adolescents with Ulcerative Colitis.基于巴黎分类的严重疾病活动与韩国儿童和青少年溃疡性结肠炎的肠外表现的发展相关。
J Korean Med Sci. 2021 Nov 15;36(44):e278. doi: 10.3346/jkms.2021.36.e278.
9
Pancreatic Associated Manifestations in Pediatric Inflammatory Bowel Diseases.儿科炎症性肠病的胰腺相关表现。
Genes (Basel). 2021 Aug 31;12(9):1372. doi: 10.3390/genes12091372.